After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents ...

Embecta Corporation ( (EMBC) ) has released its Q4 earnings. Here is a breakdown of the information Embecta Corporation presented to its ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

B, consensus $1.12B.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference ...

AQR Capital Management LLC lifted its stake in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 136.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC.